

Miriam Grazia Ferrara

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4157019/publications.pdf>

Version: 2024-02-01

9
papers

114
citations

1936888
4
h-index

1588620
8
g-index

9
all docs

9
docs citations

9
times ranked

225
citing authors

#	ARTICLE	IF	CITATIONS
1	Selpercatinib in RET-fusion positive metastatic non-small cell lung cancer: achievements and gray areas. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 785-794.	1.1	3
2	Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory "FoRECATT" study. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1583-1592.	2.0	12
3	Post-progression outcomes of NSCLC patients with PD-L1 expression $\geq 50\%$ receiving first-line single-agent pembrolizumab in a large multicentre real-world study. <i>European Journal of Cancer</i> , 2021, 148, 24-35.	1.3	19
4	Modern Challenges for Early-Phase Clinical Trial Design and Biomarker Discovery in Metastatic Non-Small-Cell Lung Cancer. <i>Journal of Molecular Pathology</i> , 2021, 2, 207-222.	0.5	0
5	PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non-small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors. <i>Clinical Lung Cancer</i> , 2021, 22, 351-360.	1.1	7
6	Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned. <i>Cells</i> , 2021, 10, 2685.	1.8	4
7	Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives. <i>Cancers</i> , 2020, 12, 1196.	1.7	65
8	Long-term survivors with immunotherapy in advanced NSCLC: is "cure"™ within reach?. <i>Translational Cancer Research</i> , 2020, 9, 409-414.	0.4	3
9	Exploiting MET dysregulation in EGFR-addicted non-small-cell lung carcinoma: a further step toward personalized medicine. <i>Translational Lung Cancer Research</i> , 2018, 7, S312-S317.	1.3	1